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INTRODUCTION
International Conference on Harmonization (ICH) defines “quality by design” as “a systematic approach to the product development that begins with 
predefined objectives and emphasizes on product 
and process understanding and control, based on 
sound science and quality risk management” (1). The 
quality of pharmaceutical products is evaluated during 
the lifecycle of the drug allowing the investigation of 
critical process parameters, having an impact on critical 
quality attributes. The entire pharmaceutical product 
development strategy is based upon the Target Product 
Quality Profile (TPQP), determining the design and extent 
of product development (2, 3).  
Physicochemical properties of drugs are decisive for 
choosing the excipients in the formulation development 
phase (4). In vitro dissolution data can be helpful in 
the evaluation and interpretation of possible risks (5), 
especially in the case of immediate release and modified 
release dosage forms on the dose dump and food effects 
that could influence gastrointestinal conditions (6). A 
satisfactory in vitro dissolution rate is helpful in predicting 
the pharmacokinetic properties, which impact the study 
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design for characterization of pharmaceutical products 
(7, 8). The dissolution rate is dependent on several 
formulation and process variables, and minor changes will 
result in large variation, especially with drugs with poor 
water solubility. 
In a quality-by-design approach, the dissolution rates of 
finished pharmaceutical products are evaluated in sink 
conditions to test the release of the entire dose. Products 
are discarded if they do not meet the acceptance criteria for 
approval (9). Official dissolution testing methods analyze 
various dissolution media and experimental parameters 
to determine sink conditions. Some of these methods are 
unable to discriminate among the products of different 
quality attributes (prepared with different formulations 
and under-varied processing parameters). There is 
always a need for a dissolution testing method that can 
determine the effect of different variables on dissolution 
rate. The discriminatory power of the dissolution testing 
method is its ability to detect the effect of minor changes 
in process and/or formulation on dissolution rate (10). 
Demonstration of discriminatory power of a dissolution 
method is challenging and important, particularly in 
monitoring active pharmaceutical ingredient (API) or 
formulation parameters, which are critical for optimal 
product performance. 
The liquisolid technique is a novel approach and has been 
extensively applied for enhancement of dissolution rates 
of poorly soluble drugs. A “liquisolid system” refers to 
formulations formed by conversion of liquid medication 
to a free-flowing and compressible powder (11). The 
liquid medication may be a liquid drug, drug solution, 
or dispersion in water-miscible nonvolatile solvent or 
solvent system (12). Liquisolid compacts are usually 
obtained by mixing the liquid medication (liquid drug or 
drug solution/dispersion) with the carrier material and 
blending with coating material (13). A powdered solution 
is formed on the surface of the carrier material, resulting 
in an enhanced dissolution rate. Liquisolid technology was 
introduced in 1990s, and Spireas and Sadu were pioneers 
(14). Since then, extensive research has been made to 
improve dissolution rates of several poorly soluble drugs 
by liquisolid technique. It is industrially applicable due 
to simplicity and cost effectiveness and has no stability 
issues (14–16). Recently the technique has been applied 
for preparation of sustained release products using 
hydrophobic carriers such as Eudragit RL or RS (17, 18). 
As in liquisolid compact, the drug is incorporated as 
solution or dispersion, and small changes in experimental 
parameters like drug loading and type and quantity of 
the carrier material can cause significant changes in the 
drug release profile. The systematic development of a 
dissolution method of discriminatory nature is required at 
the earlier stages of product development, as it enables 
the formulator to adopt the right approach in finalizing the 
prototype formula and process for further scale-up (19). 
In the present study, hydrochlorothiazide (HCTZ) was 
selected as a model drug due its poor solubility (20). 
Its molecular weight is 297.74 g/mol. According to the 
Biopharmaceutical Classification System (BCS), HCTZ is a 
class IV drug and has pKa value of 7.9. It is a diuretic drug 
and is commonly used as an antihypertensive agent, alone 
or in combination with the other drugs (21). The USP 
recommends 900 mL of 0.1 N HCl as dissolution medium 
for HCTZ, held at 37 ± 2 oC and agitated at 100 rpm using 
USP apparatus I (basket method). The official dissolution 
test for HCTZ tablets is not suitable for discriminating the 
dissolution profile or supporting product development 
process of liquisolid compact dosage forms. Hence, the 
objective of the study was to develop and validate a 
discriminatory dissolution testing method for liquisolid 
compact dosage forms of HCTZ. In the present study, a 
discriminatory dissolution testing method was developed 
for liquisolid compacts dosage forms of HCTZ. The 
developed method was validated in accordance with ICH 
and USP guidelines (22, 23).
MATERIALS AND METHODS
Materials
Model drug HCTZ (purity 99.52% with respect to the 
USP reference standard), was provided by Ferozsons 
Laboratories Pvt. Ltd., Nowshera, Pakistan. All other 
reagents (acetonitrile, sodium biphosphate, hydrochloric 
acid and Tween-80) were purchased from pharmaceutical 
market of Peshawar, Pakistan. All the reagents were of 
analytical grade and used as received. 
Instrumentation
Dissolution  studies  were  performed  in  a  Pharma 
Test dissolution  testing  apparatus   (Pharma  Test, 
Germany)  while the  drug  content was  determined  by 
high-performance liquid chromatography (HPLC) system 
(Perkin Elmer, USA). Purified water was prepared by 
Milli-Q system (Millipore, Milford, MA, USA). 
Determination of Equilibrium Solubility of 
Hydrochlorothiazide (HCTZ)
Flask shake method was applied for determination of 
equilibrium solubility of HCTZ in various solvents, as listed 
below (23). Access of drug was added to the test solvent 
(50 mL), sonicated for 10 min and subjected to continuous 
shaking through a mechanical flask shaker (Morgan 
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Instruments, Pakistan) for 8 h at ambient temperature. 
After completion of the shaking period, the solution 
was kept undisturbed for 1 h to achieve the equilibrium, 
filtered (Whatman filter paper #42; pore size = 2.5 µm) 
and analyzed for drug content using HPLC. 
Equilibrium solubility of HCTZ was determined in:
 1. Purified water
 2. Purified water + Tween-80 (0.5% v/v)
 3. 0.1 N HCl (official dissolution media)
 4. 0.1 N HCl + Tween-80 (0.25% v/v)
 5. Phosphate buffer
 6. Phosphate buffer + Tween-80
In each solution, drug content was determined in triplicate 
and results were presented as mean ± standard deviation 
(SD). Composition of phosphate buffer was according to 
USP and had pH 6.8.
Optimization of Dissolution Testing Conditions
Liquisolid compact dosage forms containing HCTZ (12.5 
mg) were prepared in our previous study (13) using 
combination of polyethylene glycol (PEG-400), purified 
water, and Tween-60 as a nonvolatile solvent system. 
Microcrystalline cellulose and colloidal silicon dioxide 
were used as carrier and coating material, respectively. 
Liquisolid compact dosage forms were compressed 
using round, shallow concave punches (13.5 mm) at a 
compression weight of 500 mg. Tablets from optimal 
formulation (formulation with highest dissolution 
rate) were used throughout the study. The officially 
recommended dissolution medium for HCTZ is 0.1 N 
HCl (900 mL) held at 37 ± 2 oC and agitated at 100 rpm, 
using USP apparatus I (basket method) (23). In the 
present study, experimental parameters (composition of 
dissolution medium, type of USP dissolution apparatus, 
and stirring rate) were studied to produce discriminating 
results. Composition of the various dissolution media 
tested were as follows:
 1. Purified water
 2. Purified water + Tween-80 (0.5% v/v)
 3. 0.1 N HCl
 4. 0.1 N HCl + Tween-80 (0.25% v/v)
 5. Phosphate buffer
One tablet was put into the vessel of dissolution testing 
apparatus, containing dissolution medium, at 37 ± 2 oC. 
Aliquots (5 mL) were withdrawn at specified time intervals 
(0, 5 10, 15, 30, 45, and 60 min), filtered, and analyzed for 
amount of drug release by HPLC, in triplicate (n = 3). After 
each sampling, the volume of the dissolution medium 
was corrected with the same quantity at the same 
temperature. The dissolution medium was degassed 
prior to starting the test.
The effect of USP dissolution apparatus type (apparatus 
I and II) was evaluated by comparing dissolution rates in 
developed dissolution medium using both apparatuses. 
To evaluate the effect of stirring on dissolution rate, speed 
of the apparatus was studied at 50, 75, and 100 rpm.
Determination of HCTZ Content in Dissolution 
Samples
During dissolution studies, samples (5 mL) were collected 
at specified time intervals, filtered (Whatman filter paper 
#42; pore size: 2.5 µm) and analyzed for drug content 
using HPLC. The HPLC system was equipped with an 
auto sampler, vacuum degasser, Peltier column oven, 
pump, and UV–visible detector (PerkinElmer Series 200 
system, USA). The chromatographic data was analyzed 
on PerkinElmer TotalChrom workstation software 
(version 6.3.1) linked with the LC-system through network 
chromatography interface (NCI) 900. The Hypersil BDS 
C8 column (250  × 4.6 mm, 5 µm) was used as stationary 
phase and was protected by a PerkinElmer precolumn 
guard cartridge C18 (30  × 4.6 mm, 10 µm). A combination 
of phosphate buffer and acetonitrile (9:1, v/v) was used 
as the mobile phase, pumped at a flow rate of 1.5 mL/
min at ambient temperature. The pH of the mobile 
phase was adjusted to 3 after addition of acetonitrile. 
Detector wavelength was set at 272 nm. Drug content 
of the samples was determined based on comparison of 
the area of sample solution to standard solution with the 
same concentration. The concentration of the standard 
solution was based on dose of liquisolid compact dosage 
forms (12.50 mg) and volume of dissolution media (900 
mL). 
 
Comparison of Dissolution Profiles by the Model-
Independent Method
The model-independent approach, which is based on 
similarity factor (f2) and dissimilarity factor (f1), was 
applied for comparison of dissolution profile (24, 25). An 
f2 value of 50 or greater ensures sameness or equivalence 
of the two curves.  
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Preparation of Standard Stock Solution of HCTZ
Stock solution of HCTZ was prepared by dissolving drug 
in methanol to get a concentration of 1 mg/mL. Working 
solutions were prepared daily by diluting aliquot from 
stock solution with dissolution media. Each solution was 
filtered before analysis. 
Validation of the Developed Dissolution Testing 
Method
According to the standard guidelines (22, 23), the selected 
dissolution method was validated for various parameters 
such as linearity, specificity, accuracy, precision, and 
stability. Linearity of the dissolution method was 
evaluated from the calibration curves constructed at 
seven different concentration points of HCTZ solution 
prepared in dissolution medium in the concentration 
range of 1–50 µg/mL. Specificity of dissolution method 
was evaluated by examining the effect of dissolution 
medium on peak characteristics (area, height, retention 
time, and tailing factor) of HCTZ. The selected dissolution 
medium was evaluated without drug (blank) and with 
known amount of drug using HPLC and the results was 
compared. Percent recovery was used to determine 
accuracy of the proposed dissolution method. Aliquots 
of the stock solution of HCTZ were added to dissolution 
medium (900 mL) to get the drug concentration in the 
range of 80–120% of the nominal dose and stirred at 75 
rpm for 15 min. Samples (5 mL) were withdrawn, analyzed 
for drug content, and percent recovery was calculated.
Precision of the method was determined in terms of 
repeatability and intermediate precision. For repeatability, 
the dissolution test was performed in six vessels of the 
dissolution testing apparatus simultaneously under the 
same conditions. Intermediate precision was evaluated 
based on intraday and interday studies. 
Stability Study of Solutions
Stability of the solutions was determined at three 
temperatures (low: 5 ± 3 oC, ambient: 24 ± 3 oC, and 
elevated: 40 ± 3 oC) for 7 days. Stock solution of HCTZ 
was diluted with the selected dissolution medium 
(combination of purified water and Tween-80) to the 
specified concentration (20 µg/mL). Each solution (stock 
solution, solution prepared in official dissolution medium, 
and solution prepared in developed dissolution media) 
was divided into three portions (n = 3) and stored at the 
specified temperatures for 7 days. After completion of the 
study period, percent recovery of HCTZ was calculated 
and results were presented as mean ± SD; %RSD. 
RESULTS AND DISCUSSION
HCTZ is a diuretics agent that is available as a tablet 
dosage form, alone, and in combination with other drugs 
like losartan and valmisartan. Liquisolid compact dosage 
forms of HCTZ (12.5 mg) prepared in one of our previous 
studies (13) were used in the study. For dissolution testing 
of HCTZ, USP recommends 0.1 N HCl as the dissolution 
medium and USP apparatus I (basket) stirred at 100 rpm 
(23). The official dissolution testing method is unable to 
discriminate among different formulations of liquisolid 
compact dosage forms due to higher solubility. So, the 
objective of this study was to develop and validate a 
dissolution method for liquisolid compact dosage forms 
of HCTZ that can discriminate the dissolution profile of 
the formulations of varying nature. 
Equilibrium Solubility of HCTZ
Solubility plays a prime role in the dissolution of a 
drug substance. Correlations between solubility and 
dissolution rate of different drug substances in various 
media are well-established. The results of the solubility 
study and the influence of sink conditions of HCTZ are 
presented Figure 1. Strength of liquisolid compact dosage 
forms of HCTZ was 12.5 mg (i.e., each liquisolid compact 
contained 12.5 mg of HCTZ) and the ratio of solubility (Cs) 
to the dose (Cd) was used to predict the sink conditions. 
A sink condition occurs when the amount of drug that 
can be dissolved in the dissolution medium is three times 
greater than the amount of drug to be dissolved (10). A 
low Cs/Cd ratio shows the existence of non-sink conditions 
with a subsequent lower dissolution rate. Based on 
solubility, sink conditions can be achieved using 0.1 N HCl 
and phosphate buffer as dissolution medium, with and 
without surfactants. Non-sink conditions were expected 
using purified water (with and without surfactant) due to 
a smaller dose solubility ratio (< 3). 
Figure 1.  Equilibrium solubility of HCTZ in various dissolution media and 
correlation with sink conditions. Equilibrium solubility was determined at 
ambient temperature; horizontal line shows sink condition (C
�
/Cd = 3). 
HCl, hydrochloric acid; HCTZ, hydrochlorothiazide.
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Selection of Discriminatory Dissolution Test 
Conditions
The suitable dissolution test conditions were selected 
based on the screening study conducted on liquisolid 
compacts of HCTZ. Dissolution rates were determined 
in different dissolution media (purified water, purified 
water + Tween-80, 0.1 N HCl, 0.1 N HCl + Tween-80, and 
phosphate buffer). We evaluated the effect of different 
USP dissolution testing apparatuses and rotation speed, 
and the conditions with better discriminatory power 
were selected. 
Selection of Dissolution Medium
The highest dissolution rate was observed with the 
officially recommended dissolution medium (0.1 N HCl), 
irrespective of the stirring rate due to sink conditions 
(C�/Cd > 3). Inclusion of Tween-80 further increased its 
dissolution rate, and most of the drug (71.08 ± 0.83%) 
released within 15 min, as shown in Figure 2. Except 
for purified water, abrupt release was observed in all 
tested dissolution media. HCTZ is practically insoluble 
in water; incomplete drug release (59.67 ± 1.31%) at 
a very slow rate was observed using purified water as 
dissolution medium. Inclusion of Tween-80 into purified 
water increased the dissolution rate. It was observed that 
100% of drug released from liquisolid compacts within 
60 min in 900 mL of purified water and Tween-80 (0.5%, 
v/v). Moreover, the dissolution rate was relatively slower 
and consistent, irrespective of rotation speed of USP 
apparatus I (basket). Surfactant increased solubility of 
HCTZ due to its wetting and micelle solubilization action 
(26). The use of surfactants in the dissolution media for 
sparingly soluble drugs is physiologically relevant and 
well-documented (27). A dissolution medium containing 
surfactant can better simulate the environment of the 
gastrointestinal tract than a medium containing organic 
solvents or other nonphysiological substances (28). The 
addition of a small amount of surfactant below its critical 
micelle concentration is often sufficient to solubilize 
certain drug products. In those cases where a higher 
concentration of surfactant leads to faster dissolution, 
any potential correlation with in vivo performance is lost 
(28). Therefore, a low concentration of surfactant is a 
modifier of choice. In the present study, consistent drug 
release at a better rate was observed in purified water 
containing Tween-80 (0.5% v/v), so this was selected as 
dissolution medium. 
Figure 2.  In vitro drug release from liquisolid compacts of HCTZ in 900 mL 
of dissolution media of varying nature. A: 0.1 N HCl (official dissolution 
medium for HCTZ); B: 0.1 N HCl + Tween-80 (0.25% v/v); C: purified water; 
D: purified water + Tween-80 (0.5%, v/v); E: phosphate buffer (pH 6.8). 
Dissolution rate was determined using USP apparatus I (basket). At each 
sampling point, drug content was determined in triplicate, and the mean, 
SD, and SE (error bars) were calculated. HCl, hydrochloric acid, HCTZ, 
hydrochlorothiazide; SE, standard error. 
Type and Speed of USP Dissolution Testing Apparatus
Different dissolution rates of HCTZ were observed with 
USP apparatus I (basket) and II (paddle). Dissolution rates 
were relatively higher with apparatus II, and most of the 
drug released during the first 15 min. The difference 
between the two types of apparatuses was insignificant 
(less than 1%) in terms of maximum drug release (i.e., the 
same amount of drug was released at end of the test). 
Compared with apparatus II, apparatus I resulted in drug 
release at a slower and consistent rate, as shown in Figure 
3, so apparatus I was selected for further study.
Figure 3.  Dissolution rate of HCTZ from liquisolid compacts determined 
with USP apparatus I (basket) and II (paddle) using the developed 
dissolution medium (purified water + Tween-80, 0.5% v/v) at 37 ± 2 oC. 
At each sampling point, drug content was determined in triplicate, and 
the mean, SD (error bars), and SE were calculated. HCTZ, 
hydrochlorothiazide; SE, standard error.
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Liquisolid compacts of HCTZ exhibited different 
dissolution profiles at different levels of basket speed 
(50, 75, and 100 rpm). The dissolution rate increased with 
increasing speed of the basket, as shown in Figure 4. At 
100 rpm, burst drug release was observed within initial 
10 min, making it difficult to discriminate among different 
formulations. On the other hand, incomplete drug release 
(63.48 ± 1.59%; n = 3) was observed at lowest speed 
(50 rpm). Consistent drug release at optimum rate was 
observed at 75 rpm, so this was selected as rotation 
speed of the basket. 
USP apparatus I, at 75 rpm, and 900 mL of purified water 
containing 0.5% Tween-80 were chosen as conditions for 
dissolution testing of liquisolid compacts. 
Confirmation of Discriminatory Dissolution Test 
Conditions
For confirmation of discriminatory dissolution test 
conditions, liquisolid compacts of HCTZ were prepared 
at different load factors, and drug release was studied 
using the selected dissolution medium (purified water 
+ Tween-80) under optimal test conditions (900 mL of 
dissolution medium held at 37 ± 2 oC and basket speed of 
75 rpm). Different dissolution profiles were obtained with 
liquisolid compact of varying nature (i.e., different load 
factors, 0.25 and 0.50), as shown in Figure 5. Drug release 
from both types of liquisolid compacts was similar in the 
official dissolution medium, indicating its indiscriminative 
nature. HCTZ is highly soluble in the official dissolution 
media and the drug is released quickly, masking the effect 
of variables (liquid load factor). The liquid load factor is 
defined as the ratio of the weight of liquid medication 
to weight of the carrier powder and is calculated by the 
following equation: Lf = W / Q, where Lf is the liquid load 
factor, W is the weight of the liquid medication (solvent 
and drug), and Q is the weight of the carrier powder. 
A higher liquid load factor value indicates more liquid 
medication in the system and vice versa. Liquid medication 
consists of nonvolatile solvent system and the API. Liquid 
load factor is usually increased by increasing nonvolatile 
solvent, as the amount of API (desired dose) is always 
constant. By increasing liquid load factor, the amount 
of the solvent increases and API is diluted, resulting in 
higher dissolution rate and vice versa. In the present 
study, using the developed dissolution testing method, 
different dissolution profiles were obtained. The model-
independent approach, based on f2 and f1, was applied 
for comparison of dissolution profiles. Values of similarity 
Figure 4.  In vitro drug release from liquisolid compacts of HCTZ 
determined at different speeds (50, 75, and 100 rpm) using USP apparatus 
I (basket) in 900 mL of dissolution medium (purified water + 0.5% 
Tween-80), at 37 ± 2 oC. At each sampling point, drug content was 
determined in triplicate, and the mean and SD (error bars) were calculated. 
HCTZ, hydrochlorothiazide.
A
B
Figure 5.  In vitro drug release from liquisolid compacts of HCTZ, with high 
(0.50) and low (0.25) load factor, determined in official dissolution medium 
(0.1 N HCl) (A) and developed dissolution medium (purified water + 
Tween-80 0.5%, v/v) (B) at constant volume (900 mL) and basket speed 
(75 rpm). At each sampling point, drug content was determined in 
triplicate and the mean and SD (error bars) were calculated. HCl, 
hydrochloric acid; HCTZ, hydrochlorothiazide.
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factor (f2 = 39) and dissimilarity factor (f1 = 72) confirmed 
dissimilarity of the dissolution profiles of liquisolid 
compact with different load factor values, as determined 
in the developed and official dissolution medium. 
Based on the above results, the dissolution test conditions 
(purified water + Tween-80, 0.5% v/v) were considered 
as discriminative because of differentiation between the 
products with different pharmaceutical attributes (i.e., 
variation in liquid load factor). 
Validation of the Developed Dissolution Testing 
Method
Based on the above results, 900 mL of purified water 
containing Tween-80 (0.5%, w/v) with a basket (USP 
apparatus I) speed of 75 rpm was selected as discriminative 
dissolution test conditions for liquisolid compacts of HCTZ. 
The developed dissolution testing method was validated 
according  to  the  standard  (USP  and  ICH)  guidelines 
(22, 23). 
Regression analysis of calibration curve, constructed 
at seven concentration levels in the range of 1–50 µg/
mL, showed that the method is quite linear. Regression 
equation and correlation coefficient values of calibration 
curves are presented in Table 1, indicating linearity of the 
method. 
Specificity of the method was estimated based on 
chromatographic response of the blank dissolution 
medium and dissolution medium containing different 
concentrations of HCTZ. Chromatogram of dissolution 
medium was free of any interfering peaks while different 
concentrations of HCTZ exhibited peaks with concentration 
dependent area and constant retention time. Peak purity 
was confirmed by examining with the peak purity tool, 
provided in the HPLC software. The obtained value for the 
peak purity was approximately 1, indicating high purity. 
Accuracy of the method was evaluated based on percent 
recovery, and values in the range of 95%–105% are 
considered acceptable. The mean recovery for HCTZ was 
in the range of 98%–100%, as shown in Table 1, indicating 
high accuracy of the method.
Precision of the method was evaluated based on 
repeatability using intraday and interday studies; results 
are summarized in Table 1. The %RSD value is less than 
1%, indicating good precision of the method.
Parameter Result (Mean ± SD; %RSD)
Linearity
Calibration Range 1 – 50 µg/mL
Regression Equation Y = 0.0269X
Correlation Co-efficient (R2) 0.9974
Accuracy
10 mg (80%) 99.09 ± 0.73; 0.74
12.5 mg (100%) 99.63 ± 0.41; 0.41
15 mg (120%) 98.57 ± 0.67; 0.68
Precision
Repeatability
Vessel-1 (V1) 100.10 ± 0.67; 0.67
Vessel-2 (V2) 99.63 ± 0.41; 0.41
Vessel-3 (V3) 99.80 ± 0.93; 0.93
Vessel-4 (V4) 99.51 ± 0.63; 0.63
Vessel-5 (V5) 99.79 ± 0.86; 0.86
Vessel-6 (V6) 100.53 ± 0.69; 0.69
Intraday Reproducibility
8 h 100.10 ± 0.67; 0.67
16 h 99.30 ± 0.29; 0.29
24 h 99.48 ± 0.53; 0.53
Interday Reproducibility
Day 1 100.10 ± 0.67; 0.67
Day 2 98.92 ± 0.33; 0.33
Day 3 99.60 ± 0.81; 0.81
Stability of Solution
Stability of the HCTZ solution prepared in dissolution 
medium was evaluated at three different temperatures 
and compared with the solution prepared in methanol and 
in the official dissolution medium. The drug content of the 
samples was within 99%–100% (Table 2) of the initial value 
over the test period (7 days), and no degradation products 
were observed in any of the chromatograms, indicating 
stability of HCTZ in dissolution medium.
Table 1. Validation Parameters for Discriminatory Dissolution 
Testing Method Developed for Liquisolid Compact Dosage Forms of 
HCTZ (n = 3) 
Dissolution medium: 900 mL purified water + Tween-80 (0.5%) at 37 ± 
2 oC; basket speed: 75 rpm. HCTZ, hydrochlorothiazide; RSD, relative 
standard deviation. 
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Composition of 
Solvent
Percent Recovery (Mean ± SD)
Ambient 
Temperature 
(24 ± 3 oC)
Lower 
Temperature
(5 ± 3 oC)
Elevated 
Temperature
(40 ± 3 oC)
Stock solution 99.31 ± 0.69 99.46 ± 0.78 99.38 ± 0.63
Developed dissolution 
medium 99.89 ± 0.72 99.93 ± 0.59 99.21 ± 0.81
Official dissolution 
medium 99.04 ± 0.60 99.90 ± 0.67 99.34 ± 0.95
CONCLUSION
A robust, discriminating dissolution testing method was 
developed for liquisolid compacts of HCTZ and validated 
according to the standard guidelines (USP and ICH). An 
initial study was conducted by evaluating the dissolution 
profiles of liquisolid compacts in different dissolution media 
using USP apparatus I and II at different speeds (50, 75, and 
100 rpm). The use of 900 mL of purified water containing 
Tween-80 (0.5% v/v) as the dissolution medium, at 37 ± 
0.5 oC, and apparatus I at 75 rpm produced satisfactory 
results. Dissolution profiles of liquisolid compacts, having 
different load factors resulted in different dissolution 
profiles, confirming the discriminatory nature of the 
method. Comparison of the obtained dissolution profiles 
using similarity and dissimilarity factors showed significant 
differences. The developed dissolution method will be 
helpful in formulation development of liquisolid compacts 
and assessment of quality and performance of different 
batches.
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